CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in children (6 years of age and older), teenagers and adults with Hereditary Angioedema (HAE).
CINRYZE was the first C1 esterase inhibitor (C1-INH) approved by the FDA to help prevent swelling attacks in children (6 years of age and older), teenagers and adults. Available since 2008, CINRYZE has successfully been used to help reduce the frequency, severity, and length of attacks in adolescent and adult patients. In pediatric patients (age 6 to 11), CINRYZE was shown to reduce the number of HAE attacks, lessen the severity of attacks, and reduce the use of acute treatment.
How does CINRYZE work?
Most people with HAE don't have enough of a protein called C1 esterase inhibitor (C1-INH), or this protein does not work correctly, which leads to a cascade of events in the body. This cascade causes another protein, called plasma kallikrein, to trigger the release of a third protein, called bradykinin. The release of too much bradykinin causes small blood vessels to release fluid in certain parts of the body, resulting in the localized swelling and pain of an HAE attack. CINRYZE® (C1 esterase inhibitor [human]) increases plasma levels of C1-INH, thereby preventing the generation of excess bradykinin to reduce the risk of a swelling attack.
Untreated person with HAE during an attack
Missing or dysfunctional C1-INH causes increased levels of bradykinin
Person with HAE after resolution of an attack
CINRYZE increases plasma levels of C1-INH to prevent the production of excess bradykinin
Blood Vessel Wall
Bradykinin B2 receptor
Missing/dysfunctional C1 esterase inhibitor
Want to learn more about an HAE treatment option that works differently from CINRYZE? Click here to learn more about one option to prevent HAE attacks in people 12 years of age and older.
Talk to your doctor about CINRYZE
Are you ready to see if preventive therapy might be right for you or your child? Take the first step by talking with your doctor.
You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.
Tell your healthcare provider about all of your medical conditions, including if you have an indwelling catheter/access device in one of your veins; have a history of blood clots, heart disease, or stroke; or are taking birth control pills or androgens. Also tell your healthcare provider if you are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed. It is not known if CINRYZE can harm your unborn baby, or if CINRYZE passes into your milk and if it can harm your baby.
Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, hives.
Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid heart rate, numbness or weakness on one side of the body.
Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA.